Glythera Wins Grant to Develop ADCs against Challenging Cancers

05:32 EDT 6 Jun 2017 | Genetic Engineering News

Glythera won a £1 million (approximately $1.3 million) grant from Innovate UK to support the development of antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers. The project will harness the U.K. firm’s PermaLink ® non-maleimide conjugation platform and portfolio of toxins and antibodies to develop ADCs targeting antigens that are overexpessed on difficult-to-treat tumors. Glythera said it will work with Covance on the program, and aims to select an initial candidate to take into first-in-man studies in 2019. “The funding by Innovate UK will help us identify novel antibody-drug conjugates for the potential treatment of a variety of cancers that are associated with high relapse rates to current treatment," commented Dr. Dave Simpson, Glythera’s CEO. “These will then be prioritised for preclinical development. With Innovate UK’s support, we aim to build a portfolio of much needed, safe treatments to improve the lives of patients living with these devastating ...

Original Article: Glythera Wins Grant to Develop ADCs against Challenging Cancers


More From BioPortfolio on "Glythera Wins Grant to Develop ADCs against Challenging Cancers"

Quick Search

Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...